mFOLFOX-6/Bevacizumab奏效的播散性骨髓癌引起的直肠低分化型腺癌的1例

野中 健太郎, 清悟 車, 通裕 伊東, 一彦 野中, 若樹 山中
{"title":"mFOLFOX-6/Bevacizumab奏效的播散性骨髓癌引起的直肠低分化型腺癌的1例","authors":"野中 健太郎, 清悟 車, 通裕 伊東, 一彦 野中, 若樹 山中","doi":"10.11405/NISSHOSHI.107.1151","DOIUrl":null,"url":null,"abstract":": A 45-year-old woman, complaining of back pain and bloody stool was given a diagnosis of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis to bone marrow and disseminated intravascular coagulation syndrome (DIC). We started chemotherapy using mFOLFOX-6 with simultaneous DIC treatment. After we confirmed that DIC had improved following 2 courses of mFOLFOX-6, bevacizumab was added to mFOLFOX-6. Laboratory studies revealed a serum CEA level of 314.4ng/ml, which improved to 4.6ng/ml after a total of 6 courses of chemotherapy. Colonoscopy findings showed almost normal rectal mucosa after a total of 10 courses of chemotherapy. Outpatient treatment was started after 5 courses of chemotherapy, and was continuing according to schedule at 7 months from the onset of this disease.","PeriodicalId":341053,"journal":{"name":"The Japanese journal of gastro-enterology","volume":"1018 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2010-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"mFOLFOX-6/Bevacizumabが奏効した播種性骨髄癌症で発症した直腸低分化型腺癌の1例\",\"authors\":\"野中 健太郎, 清悟 車, 通裕 伊東, 一彦 野中, 若樹 山中\",\"doi\":\"10.11405/NISSHOSHI.107.1151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": A 45-year-old woman, complaining of back pain and bloody stool was given a diagnosis of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis to bone marrow and disseminated intravascular coagulation syndrome (DIC). We started chemotherapy using mFOLFOX-6 with simultaneous DIC treatment. After we confirmed that DIC had improved following 2 courses of mFOLFOX-6, bevacizumab was added to mFOLFOX-6. Laboratory studies revealed a serum CEA level of 314.4ng/ml, which improved to 4.6ng/ml after a total of 6 courses of chemotherapy. Colonoscopy findings showed almost normal rectal mucosa after a total of 10 courses of chemotherapy. Outpatient treatment was started after 5 courses of chemotherapy, and was continuing according to schedule at 7 months from the onset of this disease.\",\"PeriodicalId\":341053,\"journal\":{\"name\":\"The Japanese journal of gastro-enterology\",\"volume\":\"1018 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Japanese journal of gastro-enterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11405/NISSHOSHI.107.1151\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Japanese journal of gastro-enterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11405/NISSHOSHI.107.1151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

一名45岁女性,主诉背部疼痛和便血,诊断为直肠低分化腺癌伴弥散性骨髓癌及弥散性血管内凝血综合征(DIC)。我们开始使用mFOLFOX-6进行化疗,同时进行DIC治疗。在我们确认在mFOLFOX-6治疗2个疗程后DIC得到改善后,我们将贝伐单抗添加到mFOLFOX-6中。实验室研究显示血清CEA水平为314.4ng/ml,化疗6个疗程后改善至4.6ng/ml。经过10个疗程的化疗,结肠镜检查结果显示直肠粘膜基本正常。化疗5个疗程后开始门诊治疗,发病后7个月按计划继续治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
mFOLFOX-6/Bevacizumabが奏効した播種性骨髄癌症で発症した直腸低分化型腺癌の1例
: A 45-year-old woman, complaining of back pain and bloody stool was given a diagnosis of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis to bone marrow and disseminated intravascular coagulation syndrome (DIC). We started chemotherapy using mFOLFOX-6 with simultaneous DIC treatment. After we confirmed that DIC had improved following 2 courses of mFOLFOX-6, bevacizumab was added to mFOLFOX-6. Laboratory studies revealed a serum CEA level of 314.4ng/ml, which improved to 4.6ng/ml after a total of 6 courses of chemotherapy. Colonoscopy findings showed almost normal rectal mucosa after a total of 10 courses of chemotherapy. Outpatient treatment was started after 5 courses of chemotherapy, and was continuing according to schedule at 7 months from the onset of this disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信